Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
OMGA

OMGA - Omega Therapeutics, Inc. Stock Price, Fair Value and News

2.40USD-0.02 (-0.83%)Market Closed

Market Summary

OMGA
USD2.40-0.02
Market Closed
-0.83%

OMGA Stock Price

View Fullscreen

OMGA RSI Chart

OMGA Valuation

Market Cap

133.5M

Price/Earnings (Trailing)

-1.45

Price/Sales (Trailing)

27.03

Price/Free Cashflow

-1.71

OMGA Price/Sales (Trailing)

OMGA Profitability

Return on Equity

-223.14%

Return on Assets

-50.24%

Free Cashflow Yield

-58.48%

OMGA Fundamentals

OMGA Revenue

Revenue (TTM)

4.9M

Rev. Growth (Yr)

357.36%

Rev. Growth (Qtr)

138.75%

OMGA Earnings

Earnings (TTM)

-92.3M

Earnings Growth (Yr)

20.37%

Earnings Growth (Qtr)

0.42%

Breaking Down OMGA Revenue

52 Week Range

1.806.18
(Low)(High)

Last 7 days

30.1%

Last 30 days

13.6%

Last 90 days

-28.6%

Trailing 12 Months

-65.5%

How does OMGA drawdown profile look like?

OMGA Financial Health

Current Ratio

2.87

Debt/Equity

0.34

Debt/Cashflow

-5.41

OMGA Investor Care

Shares Dilution (1Y)

0.24%

Diluted EPS (TTM)

-1.66

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.9M000
20232.3M2.6M2.8M3.1M
2022626.4K1.1M1.6M2.1M
2021000144.0K

Tracking the Latest Insider Buys and Sells of Omega Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 02, 2023
young richard a
sold
-40,000
8.00
-5,000
-
May 01, 2023
young richard a
sold
-40,000
8.00
-5,000
-
Apr 06, 2023
young richard a
sold
-40,000
8.00
-5,000
-
Mar 17, 2023
young richard a
sold
-80,000
8.00
-10,000
-
Feb 27, 2023
flagship pioneering inc.
bought
11,525,200
5.78
1,993,990
-
Feb 27, 2023
flagship pioneering inc.
bought
7,683,490
5.78
1,329,320
-
Jan 10, 2023
young richard a
sold
-160,000
8.00
-20,000
-
Sep 14, 2022
young richard a
sold
-80,000
8.00
-10,000
-
Feb 01, 2022
karande mahesh
acquired
5,989
0.53
11,300
president and ceo
Aug 03, 2021
berry david a
bought
902,394
17.00
53,082
-

1–10 of 16

Which funds bought or sold OMGA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Artal Group S.A.
unchanged
-
846,885
4,830,880
0.12%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.92
-3,130
8,943
-%
May 16, 2024
Colony Group, LLC
new
-
25,000
25,000
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-94,096
-
-%
May 15, 2024
Cubist Systematic Strategies, LLC
new
-
64,764
64,764
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
added
1,137
1,114,520
1,194,080
-%
May 15, 2024
MARSHALL WACE, LLP
new
-
217,346
217,346
-%
May 15, 2024
AMUNDI
sold off
-100
-110,921
-
-%
May 15, 2024
Flagship Pioneering Inc.
unchanged
-
18,704,400
106,673,000
7.00%
May 15, 2024
683 Capital Management, LLC
unchanged
-
73,600
419,750
0.03%

1–10 of 48

Are Funds Buying or Selling OMGA?

Are funds buying OMGA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own OMGA
No. of Funds

Unveiling Omega Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 12, 2024
fmr llc
-
0
SC 13G/A
Feb 09, 2024
harbourvest partners l.p.
6.4%
3,512,110
SC 13G/A
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Mar 10, 2023
fmr llc
-
0
SC 13G/A
Feb 27, 2023
flagship ventures fund v, l.p.
2.0%
1,088,470
SC 13D/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 14, 2022
harbourvest partners l.p.
5.5%
2,647,059
SC 13G
Feb 09, 2022
fmr llc
-
0
SC 13G

Recent SEC filings of Omega Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 24, 2024
8-K
Current Report
Jun 21, 2024
3
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading

Peers (Alternatives to Omega Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-17.75% 15.65%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
50.83% 15.66%
-84.91
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
12.78% -8.91%
78.69
6.54
13.74% 186.89%
14.3B
3.8B
11.22% 2.07%
19.2
3.8
8.58% 129.81%
MID-CAP
4.7B
524.1M
-5.39% -54.95%
-11.17
8.9
394.93% 39.61%
4.3B
107.9M
-17.68% 46.87%
-7.87
48.09
54.84% -28.31%
3.7B
251.0M
4.40% -10.91%
-12.58
14.85
73.58% -86.73%
3.4B
240.7M
9.49% -22.70%
-7.15
12.77
-1.03% -213.92%
2.6B
813.8M
4.41% -35.25%
-1.5K
3.22
56.43% 98.83%
2.0B
996.6M
-9.61% 109.10%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.09% 16.96%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-3.44% 394.54%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-27.55% 54.46%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-4.57% 211.94%
-0.78
7.61
-13.45% 69.54%

Omega Therapeutics, Inc. News

Latest updates
Yahoo Sport Australia23 hours ago
Yahoo New Zealand News23 Jun 202408:20 am
Defense World06 Jun 202407:00 am
Markets Insider07 May 202407:00 am

Omega Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Revenue138.7%2,360989831759516735595476268-
Operating Expenses5.2%22,81121,68823,73431,59926,33431,70226,58026,33020,22720,808
  S&GA Expenses23.0%7,3966,0127,8696,2066,2437,0365,1986,2025,4065,727
  R&D Expenses-1.5%15,41515,65316,47525,01220,09126,87920,67019,38714,19114,644
Interest Expenses-32.0%331487684957682248184-55.00-155-571
Net Income0.4%-20,129-20,214-22,248-29,687-25,279-30,826-25,799-25,912-20,164-20,854
Net Income Margin40.7%-18.69*-31.48*-38.04*-42.85*-46.44*-49.53*-58.28*-77.08*-119.67*-474.17*
Free Cashflow32.2%-12,335-18,191-23,724-23,581-28,403-24,529-25,163-26,701-23,502-16,156
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22020Q4
Assets-10.1%18420421822915614617019321723324313028.00
  Current Assets-21.1%71.0090.0010212514913816118320622923912524.00
    Cash Equivalents-12.3%60.0068.0082.0010610571.0077.0091.0010618623412223.00
  Net PPE-5.6%5.005.005.006.004.004.004.004.004.004.004.004.003.00
Liabilities-2.7%14214614213333.0040.0036.0036.0036.0033.0023.0022.0017.00
  Current Liabilities-7.9%25.0027.0027.0034.0018.0022.0015.0014.0014.0012.0014.0012.008.00
  Long Term Debt-6.6%14.0015.0016.0012.0014.0017.0020.0020.0020.0020.007.009.009.00
    LT Debt, Current0%4.004.004.008.006.003.00----5.003.003.00
    LT Debt, Non Current-6.6%14.0015.0016.0012.0014.0017.0020.0020.0020.0020.007.009.009.00
Shareholder's Equity-28.7%41.0058.0076.0096.00123106134157181201220--
  Retained Earnings-6.0%-354-334-314-292-262-237-206-180-154-134-113-95.12-66.22
  Additional Paid-In Capital0.9%3963933903883863443413393373353343.002.00
Shares Outstanding0.0%55.0055.0055.0055.0051.0048.0048.0048.0048.0048.0014.005.00-
Float----140---80.00-----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q2
Cashflow From Operations30.9%-11,800-17,080-23,020-23,289-28,111-24,237-24,835-26,093-23,350-15,956-16,496-14,608-10,549---
  Share Based Compensation62.4%3,4312,1132,2802,1782,2222,1221,9742,0531,6041,1821,123685194---
Cashflow From Investing108.6%4,4652,140-72424,04922,05017,65210,58811,267-57,567-39,132-353-866-48.00---
Cashflow From Financing-165.8%-1,0701,625-8.0021939,9875864.0035.0083.007,295128,713118125,413---
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

OMGA Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Collaboration revenue$ 2,360$ 516
Operating expenses:  
Research and development15,41520,091
General and administrative7,3966,243
Total operating expenses22,81126,334
Loss from operations(20,451)(25,818)
Other Income (expense), net:  
Interest income, net331682
Other expense, net(9)(143)
Total other income, net322539
Net loss$ (20,129)$ (25,279)
Net loss per common stock attributable to common stockholders, basic$ (0.36)$ (0.5)
Net loss per common stock attributable to common stockholders, diluted$ (0.36)$ (0.5)
Weighted-average common stock used in net loss per share attributable to common stockholders, basic55,150,50750,627,287
Weighted-average common stock used in net loss per share attributable to common stockholders, diluted55,150,50750,627,287
Comprehensive loss:  
Net Income (Loss)$ (20,129)$ (25,279)
Other comprehensive income (loss):  
Unrealized gain on marketable securities14251
Comprehensive loss$ (20,115)$ (25,028)

OMGA Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 60,033$ 68,443
Marketable securities 4,986
Accounts receivable, due from related party1,1491,006
Accounts receivable 5,125
Prepaid expenses and other current assets9,70810,324
Total current assets70,89089,884
Property and equipment, net5,0135,311
Operating lease right-of-use assets, net107,362108,736
Restricted cash341341
Other assets7494
Total assets183,680204,366
Current liabilities:  
Accounts payable1,5791,620
Accrued expenses4,4927,914
Other current liabilities2,6201,972
Lease liabilities, current11,98911,300
Long-term debt, current portion4,0004,000
Total current liabilities24,68026,806
Lease liabilities, non-current97,72998,243
Long-term debt, net13,89714,885
Other liabilities6,0206,416
Total liabilities142,326146,350
Commitments and contingencies (Note 9)
Stockholders' equity:  
Preferred stock, $0.001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Common stock, $0.001 par value; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 55,154,985 and 55,144,982 issued and outstanding as of March 31, 2024 and December 31, 2023, respectively5555
Additional paid-in capital396,062392,609
Accumulated other comprehensive loss (14)
Accumulated deficit(354,763)(334,634)
Total stockholders' equity41,35458,016
Total liabilities and stockholders' equity$ 183,680$ 204,366
OMGA
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://omegatherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES116

Omega Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Omega Therapeutics, Inc.? What does OMGA stand for in stocks?

OMGA is the stock ticker symbol of Omega Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Omega Therapeutics, Inc. (OMGA)?

As of Mon Jun 24 2024, market cap of Omega Therapeutics, Inc. is 133.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OMGA stock?

You can check OMGA's fair value in chart for subscribers.

What is the fair value of OMGA stock?

You can check OMGA's fair value in chart for subscribers. The fair value of Omega Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Omega Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OMGA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Omega Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether OMGA is over valued or under valued. Whether Omega Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Omega Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMGA.

What is Omega Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Jun 24 2024, OMGA's PE ratio (Price to Earnings) is -1.45 and Price to Sales (PS) ratio is 27.03. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMGA PE ratio will change depending on the future growth rate expectations of investors.